{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T15:38:07Z","timestamp":1712331487326},"reference-count":37,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2007,11,1]],"date-time":"2007-11-01T00:00:00Z","timestamp":1193875200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2007,11]]},"DOI":"10.1016\/j.ejim.2007.02.010","type":"journal-article","created":{"date-parts":[[2007,7,10]],"date-time":"2007-07-10T09:06:31Z","timestamp":1184058391000},"page":"510-515","source":"Crossref","is-referenced-by-count":2,"title":["Personalized therapy for chronic viral hepatitis C in the naive patient: How can we optimize treatment duration as a function of viral genotype?"],"prefix":"10.1016","volume":"18","author":[{"given":"Eric","family":"Nguyen-Khac","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominique","family":"Capron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandrine","family":"Castelain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Fran\u00e7ois","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alain","family":"Braillon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejim.2007.02.010_bib1","doi-asserted-by":"crossref","first-page":"875","DOI":"10.7326\/0003-4819-127-10-199711150-00003","article-title":"Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy","volume":"127","author":"Marcellin","year":"1997","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ejim.2007.02.010_bib2","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1136\/gut.52.2.283","article-title":"Long term histological improvement and clearance of intrahepatic hepatitis C virus RNA following sustained response to interferon-ribavirin combination therapy in liver transplanted patients with hepatitis C virus recurrence","volume":"52","author":"Bizollon","year":"2003","journal-title":"Gut"},{"key":"10.1016\/j.ejim.2007.02.010_bib3","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/j.1365-2036.2006.02785.x","article-title":"Long-term follow-up of chronic hepatitis C patients with sustained virological response to various forms of interferon-based anti-viral therapy","volume":"23","author":"Formann","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.ejim.2007.02.010_bib4","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","article-title":"Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial","volume":"358","author":"Manns","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2007.02.010_bib5","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection","volume":"347","author":"Fried","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2007.02.010_bib6","doi-asserted-by":"crossref","first-page":"346","DOI":"10.7326\/0003-4819-140-5-200403020-00010","article-title":"International Study Group. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose","volume":"140","author":"Hadziyannis","year":"2004","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ejim.2007.02.010_bib7","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1136\/gut.52.12.1784","article-title":"Treatment of hepatitis C. The 2002 French consensus","volume":"52","author":"Dhumeaux","year":"2003","journal-title":"Gut"},{"key":"10.1016\/j.ejim.2007.02.010_bib8","first-page":"1","article-title":"NIH Consensus Statement on Management of Hepatitis C: 2002","volume":"19","year":"2002","journal-title":"NIH Consens State Sci Statements"},{"key":"10.1016\/j.ejim.2007.02.010_bib9","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1002\/hep.20119","article-title":"American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C","volume":"39","author":"Strader","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.ejim.2007.02.010_bib10","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1053\/jhep.2003.50364","article-title":"Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C","volume":"38","author":"Davis","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.ejim.2007.02.010_bib11","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/S0168-8278(04)00060-1","article-title":"Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3","volume":"40","author":"Zeuzem","year":"2004","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejim.2007.02.010_bib12","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/j.1365-2893.2005.00615.x","article-title":"Clinical utility of viral load measurements in individuals with chronic hepatitis C infection on antiviral therapy","volume":"12","author":"Terrault","year":"2005","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.ejim.2007.02.010_bib13","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.cld.2005.05.009","article-title":"Use of virologic assays in the diagnosis and management of hepatitis C virus infection","volume":"9","author":"Chevaliez","year":"2005","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.ejim.2007.02.010_bib14","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/j.hep.2003.09.022","article-title":"Sampling variability of liver fibrosis in chronic hepatitis C","volume":"38","author":"Bedossa","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.ejim.2007.02.010_bib15","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/00042737-200604000-00003","article-title":"Individualization of antiviral treatment regimens for chronic hepatitis C","volume":"18","author":"Paulon","year":"2006","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.ejim.2007.02.010_bib16","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1002\/hep.20467","article-title":"Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14\u00a0weeks: A pilot study","volume":"40","author":"Dalgard","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.ejim.2007.02.010_bib17","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa042608","article-title":"Peginterferon alfa-2b and ribavirin for 12 vs. 24\u00a0weeks in HCV genotype 2 or 3","volume":"352","author":"Mangia","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2007.02.010_bib18","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1053\/j.gastro.2005.05.008","article-title":"Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24\u00a0weeks in patients with genotype 2 or 3 chronic hepatitis C","volume":"129","author":"von Wagner","year":"2005","journal-title":"Gastroenterology"},{"issue":"suppl 2","key":"10.1016\/j.ejim.2007.02.010_bib19","first-page":"734A","article-title":"Peginterferon alfa-2a (Pegasys) plus ribavirin (copegus) for 16 or 24\u00a0weeks in patients with HCV genotypes 2 or 3. final results of the accelerate trial. EASL abstract","volume":"44","author":"Shiffman","year":"2006","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejim.2007.02.010_bib20","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jhep.2005.10.003","article-title":"Efficacy of 24\u00a0weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia","volume":"44","author":"Zeuzem","year":"2006","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejim.2007.02.010_bib21","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1002\/hep.21159","article-title":"Early identification of HCV genotype 1 patients responding to 24\u00a0weeks peginterferon alpha-2a (40\u00a0kd)\/ribavirin therapy","volume":"43","author":"Jensen","year":"2006","journal-title":"Hepatology"},{"issue":"suppl 2","key":"10.1016\/j.ejim.2007.02.010_bib22","first-page":"8A","article-title":"24\u00a0week treatment regimen with peginterferon alfa-2a (40\u00a0kd) (Pegasys\u00ae) plus ribavirin (Copegus\u00ae) in HCV genotype 1 or 4 \u00ab super-responders \u00bb. EASL abstract","volume":"44","author":"Ferenci","year":"2006","journal-title":"J Hepatol"},{"issue":"suppl 2","key":"10.1016\/j.ejim.2007.02.010_bib23","first-page":"559A","article-title":"Individualized treatment strategy with peginterferon alfa-2b (Peg-IFN alfa) plus ribavirin according to early viral kinetics in hepatitis C virus (HCV) Type 1 infected patients. EASL abstract","volume":"44","author":"Berg","year":"2006","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejim.2007.02.010_bib24","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/j.1478-3231.2005.01196.x","article-title":"A randomized trial of 24-vs. 48-week courses of PEG interferon alpha-2b plus ribavirin for genotype-1b-infected chronic hepatitis C patients: a pilot study in Taiwan","volume":"26","author":"Yu","year":"2006","journal-title":"Liver Int"},{"key":"10.1016\/j.ejim.2007.02.010_bib25","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.jhep.2006.01.023","article-title":"Reply","volume":"44","author":"Zeuzem","year":"2006","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejim.2007.02.010_bib26","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1053\/j.gastro.2006.02.015","article-title":"Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72\u00a0weeks of peginterferon-alfa-2a plus ribavirin","volume":"130","author":"Berg","year":"2006","journal-title":"Gastroenterology"},{"issue":"suppl 1","key":"10.1016\/j.ejim.2007.02.010_bib27","first-page":"218A","volume":"40","author":"Sanchez-Tapias","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.ejim.2007.02.010_bib28","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/S0140-6736(98)07124-4","article-title":"Randomised trial of interferon alpha2b plus ribavirin for 48\u00a0weeks or for 24\u00a0weeks versus interferon alpha2b plus placebo for 48\u00a0weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT)","volume":"352","author":"Poynard","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2007.02.010_bib29","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1056\/NEJM199811193392101","article-title":"Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group","volume":"339","author":"McHutchison","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2007.02.010_bib30","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1111\/j.1365-2036.2004.02208.x","article-title":"Meta-analysis: a randomized trial of peginterferon plus ribavirin for the initial treatment of chronic hepatitis C genotype 4","volume":"20","author":"Khuroo","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.ejim.2007.02.010_bib31","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1136\/gut.2004.057182","article-title":"Peginterferon {alpha}-2b and ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral kinetics on sustained virological response","volume":"54","author":"Kamal","year":"2005","journal-title":"Gut"},{"key":"10.1016\/j.ejim.2007.02.010_bib32","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1111\/j.1572-0241.2005.00253.x","article-title":"Response of hepatitis C genotype-4 naive patients to 24\u00a0weeks of Peg-interferon-alpha2b\/ribavirin or induction-dose interferon-alpha2b\/ribavirin\/amantadine: a non-randomized controlled study","volume":"100","author":"El-Zayadi","year":"2005","journal-title":"Am J Gastroenterol"},{"issue":"suppl 2","key":"10.1016\/j.ejim.2007.02.010_bib33","first-page":"568A","article-title":"Efficacy and safety of the treatment with peginterferon alfa-2a (pegasys\u00ae) plus ribavirin in patients with chronic hepatitis c genotype 4: interim results","volume":"44","author":"Diago","year":"2006","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejim.2007.02.010_bib34","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jhep.2005.08.016","article-title":"Hepatitis C minimal residual viremia (MRV) detected by TMA at the end of Peg-IFN plus ribavirin therapy predicts post-treatment relapse","volume":"44","author":"Gerotto","year":"2006","journal-title":"J Hepatol"},{"issue":"suppl 2","key":"10.1016\/j.ejim.2007.02.010_bib35","first-page":"572A","article-title":"Predictive value and predictive factors of the rapid virological response in chronic hepatitis C treatment. EASL abstract","volume":"l44","author":"Galeras","year":"2006","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejim.2007.02.010_bib36","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s11894-005-0066-1","article-title":"Maintenance therapy for chronic hepatitis C","volume":"7","author":"Kelleher","year":"2005","journal-title":"Curr Gastroenterol Rep"},{"issue":"suppl 2","key":"10.1016\/j.ejim.2007.02.010_bib37","first-page":"571A","article-title":"More rapid drop of HCV RNA level under therapy and better sustained response rate in Egyptian patients versus non-Egyptian patients with HCV genotype 4","volume":"44","author":"El Ray","year":"2006","journal-title":"J Hepatol"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620507001380?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620507001380?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,6]],"date-time":"2019-01-06T01:26:55Z","timestamp":1546738015000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620507001380"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,11]]},"references-count":37,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2007,11]]}},"alternative-id":["S0953620507001380"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2007.02.010","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2007,11]]}}}